PCV72 COST-EFFECTIVENESS OF ROSUVASTATIN FOR THE PRIMARY PREVENTION OF VASCULAR EVENTS ACCORDING TO FRAMINGHAM RISK SCORE IN PATIENTS WITH AN ELEVATED C-REACTIVE PROTEIN
May 1, 2010, 00:00
10.1016/S1098-3015(10)72791-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)72791-1/fulltext
Title :
PCV72 COST-EFFECTIVENESS OF ROSUVASTATIN FOR THE PRIMARY PREVENTION OF VASCULAR EVENTS ACCORDING TO FRAMINGHAM RISK SCORE IN PATIENTS WITH AN ELEVATED C-REACTIVE PROTEIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72791-1&doi=10.1016/S1098-3015(10)72791-1
First page :
Section Title :
Open access? :
No
Section Order :
354